Cargando…

The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat

Metabolic flexibility was assessed in male Zucker rats: lean controls, obese controls, and obese rats treated with the dual peroxisome proliferator activated receptor (PPAR) α/γ agonist, tesaglitazar, 3 μmol/kg/day for 3 weeks. Whole body glucose disposal rate (R (d)) and hepatic glucose output (HGO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallenius, Kristina, Kjellstedt, Ann, Thalén, Pia, Löfgren, Lars, Oakes, Nicholas D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826326/ https://www.ncbi.nlm.nih.gov/pubmed/24285952 http://dx.doi.org/10.1155/2013/305347

Ejemplares similares

Roles of Fatty Acid Oversupply and Impaired Oxidation in Lipid Accumulation in Tissues of Obese Rats
por: Oakes, Nicholas D., et al.
Publicado: (2013)

In vivo liposomal delivery of PPARα/γ dual agonist tesaglitazar in a model of obesity enriches macrophage targeting and limits liver and kidney drug effects
por: Osinski, Victoria, et al.
Publicado: (2020)

The effect of exercise training combined with PPARγ agonist on skeletal muscle glucose uptake and insulin sensitivity in induced diabetic obese Zucker rats
por: Kim, Jae-Cheol
Publicado: (2016)

GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice
por: Quarta, Carmelo, et al.
Publicado: (2022)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Effects of Endogenous PPAR Agonist Nitro-Oleic Acid on Metabolic Syndrome in Obese Zucker Rats
por: Wang, Haiping, et al.
Publicado: (2010)

Tesaglitazar ameliorates non-alcoholic fatty liver disease and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient mice
por: ZHANG, BU-CHUN, et al.
Publicado: (2012)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists
por: Liberato, Marcelo Vizoná, et al.
Publicado: (2012)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
por: Kumar, Divya P., et al.
Publicado: (2020)

Pharmacological PPARα Activation Markedly Alters Plasma Turnover of the Amino Acids Glycine, Serine and Arginine in the Rat
por: Ericsson, Anette, et al.
Publicado: (2014)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Novel Podophyllotoxin Derivatives as Partial PPARγ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes
por: Zhang, Xiangming, et al.
Publicado: (2016)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Protection against Myocardial Ischemia-Reperfusion Injury at Onset of Type 2 Diabetes in Zucker Diabetic Fatty Rats Is Associated with Altered Glucose Oxidation
por: Povlsen, Jonas Agerlund, et al.
Publicado: (2013)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

Coenzyme A and Its Thioester Pools in Obese Zucker and Zucker Diabetic Fatty Rats
por: Chohnan, Shigeru, et al.
Publicado: (2020)

CMHX008, a PPARγ partial agonist, enhances insulin sensitivity with minor influences on bone loss
por: Hou, Yi, et al.
Publicado: (2018)

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
por: Jain, Mukul R, et al.
Publicado: (2015)

Regulation of Glial Cell Functions by PPAR-γ Natural and Synthetic Agonists
por: Bernardo, Antonietta, et al.
Publicado: (2008)

PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments
por: Veliceasa, Dorina, et al.
Publicado: (2008)

The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria
por: Serghides, Lena
Publicado: (2012)

Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist
por: Goto, Tsuyoshi, et al.
Publicado: (2011)

Honokiol: A non-adipogenic PPARγ agonist from nature()
por: Atanasov, Atanas G., et al.
Publicado: (2013)

PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
por: Vella, Veronica, et al.
Publicado: (2017)

Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts
por: Koo, Jun Bon, et al.
Publicado: (2017)

Synthesis and Biological Activity of Piperine Derivatives as Potential PPARγ Agonists
por: Wang, Yanli, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c1ctklf0sni4k21g2dud1rgf2s